Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma

BackgroundPD-1-based immune checkpoint blockade (ICB) is a highly effective therapy in metastatic melanoma. However, 40-60% of patients are primarily resistant, with valid predictive biomarkers currently missing. This study investigated the digitally quantified tumor PD-L1 expression for ICB therapy...

Full description

Bibliographic Details
Main Authors: Jan-Malte Placke, Camille Soun, Jenny Bottek, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Christiane Pfeiffer, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Edgar Dippel, Michael Weichenthal, Lisa Zimmer, Elisabeth Livingstone, Jürgen C. Becker, Georg Lodde, Antje Sucker, Klaus Griewank, Susanne Horn, Eva Hadaschik, Alexander Roesch, Dirk Schadendorf, Daniel Robert Engel, Selma Ugurel
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
PD-L1 quantification
melanoma
immune checkpoint blockade therapy
response
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.741993/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.741993/full

Similar Items